Impaired cellular immunity is the main cause of opportunis-HIV-infected adults are caused by H. influenzae type b (Hib) [11] . Invasive infections caused by Hib are potentially preventtic infections in HIV-infected individuals. However, diminished humoral immunity has also been demonstrated in vitro [1 -3] able by antibodies to the bacterial capsular polysaccharide antiand in vivo [4] , in particular with respect to T lymphocytegens. To improve immunity to Hib, vaccination of HIVdependent antigens [5, 6] . The clinical importance of impaired infected individuals could be an option. humoral immunity in HIV-infected individuals is underscored
The aim of the present study was to investigate the antibody by an increased incidence of infections due to microorganisms response of HIV-infected adults after vaccination with Hib like Streptococcus pneumoniae [7, 8] To investigate whether the carrier molecule of PRP (i.e., antibodies (data not shown).
tetanus toxoid) elicited a humoral immune response that might Antibodies to tetanus toxin were measured by the toxinhave influenced the response to PRP, a similar analysis of binding inhibition test as described elsewhere [16] . This test pre-and postvaccination antibodies to tetanus toxin and the is based on inhibition of the binding of toxin to horse antitoxininteraction between PRP and tetanus toxoid was performed. coated ELISA plates by preincubation of toxin with twofold dilutions of the serum under investigation. The lowest limit of detection of antitoxins is 0.01 IU/mL. For analysis of data, Results the concentration in sera without detectable antibodies was
Study Population
arbitrarily set at 0.005 IU/mL; concentrations of ú16 IU/mL were arbitrarily set at 32 IU/mL.
Five female and 49 male HIV-infected individuals were enrolled in the study. The mean age of HIV-infected individuals / T lymphocyte counts of ú300 1 10 6 /L (group 3). group 2; postvaccination concentrations of IgM antibody to All individuals in group 1 were treated with antiretroviral PRP were significantly lower in group 1 than in the other drugs (monotherapy with zidovudine [AZT], 9; monotherapy groups of patients and controls (table 3) . The increase in conwith didanosine [ddI], 3; combination therapy with AZT and centrations of IgM antibody to PRP was significantly lower in ddI, 9). In group 2, five individuals did not take antiretroviral group 1 than in controls. Prevaccination concentrations of IgG therapy, but 11 patients did (AZT monotherapy, 5; combination antibody to PRP did not differ significantly between the various therapy with AZT and ddI, 4; combination therapy with AZT groups. The postvaccination concentrations of IgG antibody to and zalcitabine, 2). Only three patients in group 3 took antiret-PRP and the increase in concentrations of IgG antibody to PRP roviral therapy (AZT monotherapy).
were significantly lower in group 1 than in the other groups of patients and controls (table 3) . Significantly fewer individuals
Adverse Reactions to Vaccination
in group 1 than in the other groups of patients and controls had a threefold or more rise in concentrations of IgG antibody Besides mild soreness at the site of injection that was reported by some individuals, the vaccination was well tolerated.
to PRP (figure 1). Analysis of IgG subclass antibodies to PRP (table 3) showed linear regression analysis, prevaccination concentrations of antibody to PRP and the number of CD4 / T lymphocytes were the that prevaccination concentrations of IgG1 antibody to PRP were significantly higher in group 2 than in controls; postvaccionly factors significantly associated with the postvaccination concentration of antibody to PRP. Analysis by stepwise logistic nation concentrations of IgG1 antibody to PRP in group 1 were significantly lower than those in the other patient groups and regression of the factors significantly associated with the humoral immune response to PRP showed that a CD4 / lymphocontrols, and the increase in concentrations of IgG1 antibody to PRP was lower in group 1 than in controls. Significantly cyte count of õ100 1 10 6 /L and an impaired proliferative response of lymphocytes to monoclonal antibody to CD3 were fewer individuals in group 1 than in the other groups of patients and controls had a threefold or more rise in concentrations of independently associated with an inadequate (i.e., less than threefold) increase in concentration of IgG antibody to PRP. IgG1 antibody to PRP (figure 1). Prevaccination concentrations of IgG2 antibody to PRP did not differ significantly between At higher CD4 / lymphocyte counts, no such association could be demonstrated. the various groups. Postvaccination concentrations of IgG2 antibody to PRP were lower in all three groups of patients than Antibodies to tetanus toxin. Analysis of concentrations of antibody to tetanus toxin showed that postvaccination concenin controls, although this difference was not significant. The increase in concentrations of IgG2 antibody to PRP was similar trations in group 1 were significantly lower than those in group 3 and controls (table 3) . In a bivariate analysis, the prevaccinain all groups.
In a bivariate analysis, postvaccination concentrations of tion concentration of antibody to tetanus toxin was associated with the number of CD4 / T lymphocytes. The postvaccination IgM and IgG antibodies to PRP were associated with the proliferative response of lymphocytes to monoclonal antibody to concentration of antibody to tetanus toxin was associated with the prevaccination concentration of antibody to tetanus toxin, CD3 and with the number of CD4 / lymphocytes; postvaccination concentrations of IgG1 antibody to PRP were associated the number of CD4 / lymphocytes, and the proliferative response of lymphocytes to monoclonal antibody to CD3. In a with the number of CD4 / lymphocytes. The increase in concentrations of IgM, IgG, and IgG1 antibodies to PRP was associmultiple linear regression analysis, the prevaccination concentration of antibody to tetanus toxin was the only factor signifiated only with the number of CD4 / lymphocytes. Healthy children immunized with a conjugated Hib vaccine respond mainly with IgG1 antibody formation [24] . In healthy adults vaccinated with conjugated Hib vaccine, IgG2 antibodies to PRP also contribute substantially to the IgG antibody response [25, 26] . In healthy adults vaccinated with nonconjugated Hib polysaccharide vaccine, the antibody response is dominated by IgG2, a general characteristic of T lymphocyteindependent type 2 antigens; after vaccination with proteinconjugated Hib polysaccharide vaccine (which is a T lymphocyte -dependent antigen) the antibodies to PRP are mainly IgG1, while variable but significant amounts of IgG2 are pro- Our study showed that the tetanus toxoid component of the vaccine induced antibodies to tetanus toxin in a T lymphocytedependent fashion. We did not find a correlation between precantly associated with the postvaccination concentration of anvaccination immunity to tetanus toxin and the antibody retibody to tetanus toxin. There was no correlation between the sponse to PRP. Other investigators [27, 28] reported a benefipre-and postvaccination concentrations of antibody to tetanus cial effect of carrier priming with regard to the immunogenicity toxin and the amount of antibodies to PRP that were produced of polysaccharide protein -conjugated Hib vaccines in animals after vaccination. and in healthy immunocompetent individuals. In adults, the response to Hib vaccination can be considered as a secondary antibody response because during life immunity Discussion has developed due to regular contact with Hib and/or crossreacting antigens of Escherichia coli K 100 [29] ; this contact The main conclusion to be drawn from this study is that vaccination with T lymphocyte -dependent conjugated Hib sustains a certain degree of humoral immunity. In a previous study of HIV-infected patients [6], we demonstrated that the vaccine is associated with an impaired antibody response in HIV-infected adults with low CD4 / T lymphocyte counts. This secondary antibody response to T lymphocyte -dependent vaccines (i.e., diphtheria toxoid, tetanus toxoid, and poliovirus conclusion is based on the low postvaccination concentrations of antibody to PRP and the small number of individuals with vaccines) was impaired in individuals with CD4 / T lymphocyte counts of õ300 1 10 6 /L, most prominently in patients with CD4
/ T lymphocyte counts of õ100 1 10 6 /L who exhibited a threefold or more increase in antibody levels. CD4 / T lymphocyte counts of õ100 1 10 6 /mL. In HIV-infected individuals, infections with Hib predomiThe T lymphocyte dependence of the antibody response following vaccination with conjugated Hib vaccine was demonnantly occur in patients with advanced HIV disease [9] . The mechanisms by which adult patients with HIV infection seem strated in an earlier study of HIV-infected adults with different stages of the disease [19] ; diphtheria toxoid -conjugated Hib to lose adequate protection against Hib infections are unknown. In children, concentrations of antibody protective against Hib polysaccharide vaccine was compared with Hib polysaccharide vaccine. It was shown that the increase in concentrations of have been estimated to be between 0.05 and 0.15 mg/mL when they are achieved by natural exposure to Hib [30, 31] and §1 antibody to PRP after vaccination with the conjugated vaccine was correlated with the number of CD4 / lymphocytes in the mg/mL following vaccination [32] . In the study by Steinhoff et al.
[10], prevaccination concentrations of antibody below group of patients with CD4
/ T lymphocyte counts of õ200 1 10 6 /L, while no correlation was found for individuals with the putative protective level (ú0.15 mg/mL) were described in 33% of the patients with CD4 / lymphocyte counts of õ200 higher CD4 / T lymphocyte counts. Another study [20] showed that antibody formation in adults who recently acquired HIV 1 10 6 /L and in only 9% of the individuals with higher CD4 / cell counts. In our study, only one individual had a concentrainfection (of whom 60% had CD4
/ cell counts of §500 1 10 6 /L) was normal following vaccination. It has also been demtion of IgG antibody to PRP that was below the protective level before vaccination. Whether T lymphocytes, apart from onstrated that children with advanced HIV disease elicit an / 9c37$$se10 08-19-97 12:04:49 cida UC: CID
